Alyeska Investment Group L.P. Acquires New Shares in Sionna Therapeutics, Inc. $SION

Alyeska Investment Group L.P. acquired a new stake in Sionna Therapeutics, Inc. (NASDAQ:SION) during the first quarter, Holdings Channel reports. The fund acquired 186,222 shares of the company’s stock, valued at approximately $1,948,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Jennison Associates LLC acquired a new position in Sionna Therapeutics during the first quarter worth $8,995,000. Charles Schwab Investment Management Inc. acquired a new position in Sionna Therapeutics during the first quarter worth $676,000. Aberdeen Group plc acquired a new position in Sionna Therapeutics during the first quarter worth $7,803,000. CenterBook Partners LP acquired a new position in Sionna Therapeutics during the first quarter worth $1,195,000. Finally, TD Asset Management Inc acquired a new position in Sionna Therapeutics during the first quarter worth $579,000.

Analysts Set New Price Targets

A number of research analysts have commented on SION shares. Royal Bank Of Canada started coverage on Sionna Therapeutics in a research note on Wednesday. They set a “sector perform” rating and a $22.00 price target on the stock. Raymond James Financial started coverage on Sionna Therapeutics in a research note on Tuesday. They set a “strong-buy” rating and a $45.00 price target on the stock. Finally, Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $36.00.

Sionna Therapeutics Stock Up 4.1%

Sionna Therapeutics stock opened at $24.00 on Friday. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $26.50. The stock’s fifty day simple moving average is $20.60 and its 200-day simple moving average is $15.99.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.27.

Insider Activity at Sionna Therapeutics

In related news, CEO Michael Cloonan sold 17,574 shares of the stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $24.96, for a total value of $438,647.04. Following the transaction, the chief executive officer owned 547,343 shares of the company’s stock, valued at $13,661,681.28. This represents a 3.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Elena Ridloff sold 16,098 shares of the stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $25.97, for a total value of $418,065.06. Following the completion of the transaction, the chief financial officer directly owned 48,116 shares in the company, valued at $1,249,572.52. This trade represents a 25.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 58,000 shares of company stock valued at $1,466,671 over the last quarter. 3.90% of the stock is owned by insiders.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.